Avasare et al. Am J Nephrol 2017;45:99-106  (DOI: / )

Slides:



Advertisements
Similar presentations
Sibbing D, et al. J Am Coll Cardiol 2009;53:
Advertisements

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:
Proteinuria as a Surrogate Outcome in IgA Nephropathy Ron Hogg MD Scott & White Medical Center Temple, Texas.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Trial profile Prakash Deedwania, et al. Lancet 2006; 368:
Trial profile Mann JF et al. Lancet 2008;372:
Tulsi Changulani 1,*, Jenny Bo 2, Mei-Ling Cheng 1, Andrew Tatham 1
Am J Nephrol 2013;38: DOI: / Fig. 1. Study selection process.
Characteristics IgAN (n=28) ADPKD (n=37) Male (percentage) 21 (75.0)
The Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy Kidney Blood Press Res 2016;41: DOI: /
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer.
Recurrence of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Appropriately Immunosuppressed Renal Transplant Patients: A Discussion of Two.
Severity of primary MPGN, rather than MPGN type, determines renal survival and post- transplantation recurrence risk  M.A. Little, P. Dupont, E. Campbell,
Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.
Fan et al. Am J Nephrol 2017;45:   (DOI: / )
Kuwabara et al. Am J Nephrol 2017;45:   (DOI: / )
ANCA Associated Vasculitis Secondary to Levamisole-Adultered Cocaine with Associated Membranous Nephropathy: A Case Series Collister et al. Am J Nephrol.
Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:
Bhandari et al. Am J Nephrol 2017;45: (DOI: / )
Nat. Rev. Nephrol. doi: /nrneph
Bushinsky et al. Am J Nephrol 2016;44: (DOI: / )
Impact of Cognitive Function Change on Mortality in Renal Transplant and End-Stage Renal Disease Patients Sharma et al. Am J Nephrol 2016;44: (DOI: / )
A Systematic Review and Meta-Analysis
Trial profile John A Dormandy et al. Lancet 2005;366:
Thiazide-Associated Hyponatremia, Report of the Hyponatremia Registry: An Observational Multicenter International Study Burst et al. Am J Nephrol 2017;45:
Hammoud et al. Am J Nephrol 2016;44:  (DOI: / )
Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients Sprague et al.
Benefit of immediate revascularization in women with critical limb ischemia in an intention-to-treat analysis  Jana Ortmann, MD, Eveline Nüesch, PhD,
A Pathological Scoring System to Predict Renal Outcome in Diabetic Nephropathy Am J Nephrol 2015;41: DOI: / Fig. 1. Renal survival.
End point Fenoldopam, n (%) Dopamine, n (%) p
Psychosocial Factors and 30-Day Hospital Readmission among Individuals Receiving Maintenance Dialysis: A Prospective Study Flythe et al. Am J Nephrol 2017;45:
Nat. Rev. Nephrol. doi: /nrneph
Pregnancy Outcomes in Patients with Glomerular Disease Attending a Single Academic Center in North Carolina O'Shaughnessy et al. Am J Nephrol 2017;45:
Lawrence F. Eichenfield, MD, Lisa Beck, MD 
Chapter 5: Renal Allograft Biopsy Wong Hin Seng
Svend A. Mortensen et al. JCHF 2014;2:
Enrollment and Outcomes
Renal risk scores: Progress and prospects
Long-term study of mycophenolate mofetil treatment in IgA nephropathy
Langsford et al. Am J Nephrol 2017;45:   (DOI: / )
Payan Schober et al. Am J Nephrol 2017;45:   (DOI: / )
Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]
Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]
Patient characteristics: American vs Canadian transplant patients
Baseline Characteristics of the Subjects
Volume 76, Issue 5, Pages (September 2009)
Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:
Volume 62, Issue 1, Pages (July 2002)
Nowak et al. Am J Nephrol 2016;44: (DOI: / )
Targeting Immunity in End-Stage Renal Disease
Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.
Baseline Characteristics of the Patients - Part I
Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis.
Recurrent Vascular Access Dysfunction as a Novel Marker of Cardiovascular Outcome and Mortality in Hemodialysis Patients Kim et al. Am J Nephrol 2016;44:71-80.
The estimated survival function using the Cox proportional hazards model and the mean value covariate pattern (days to recurrence, net tumor volume) for.
Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:
Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.
Frankel DS, et al. J Am Coll Cardiol. 2009;53:754-62
Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.
Relationship between time from diagnosis of type 2 diabetes to renal biopsy and the proportion of biopsies with any diabetic nephropathy (DN) and any non-diabetic.
Álvares et al. Am J Nephrol 2017;45: (DOI: / )
Absolute renal biopsy diagnosis frequencies of the most common glomerular disease subtypes according to patient age category. Absolute renal biopsy diagnosis.
Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.
Survival of subjects listed for heart transplantation with different spirometric ventilatory patterns. Survival of subjects listed for heart transplantation.
Survival of subjects listed for heart transplantation with and without spirometry. Survival of subjects listed for heart transplantation with and without.
Fistula and Survival Outcomes after Fistula Creation among Predialysis Chronic Kidney Disease Stage 5 Patients Miyamoto et al. Am J Nephrol 2017;45:  
Severity of primary MPGN, rather than MPGN type, determines renal survival and post- transplantation recurrence risk  M.A. Little, P. Dupont, E. Campbell,
Presentation transcript:

Predicting Post-Transplant Recurrence of IgA Nephropathy: The Importance of Crescents Avasare et al. Am J Nephrol 2017;45:99-106  (DOI:10.1159/000453081) Table 1. Baseline characteristics prior to renal transplantation

Predicting Post-Transplant Recurrence of IgA Nephropathy: The Importance of Crescents Avasare et al. Am J Nephrol 2017;45:99-106  (DOI:10.1159/000453081) Fig. 1. Percentage of open glomeruli with cellular or fibrocellular crescents among patients with post-transplant recurrent IgAN (closed circles) and those without recurrent IgAN (open circles).

Predicting Post-Transplant Recurrence of IgA Nephropathy: The Importance of Crescents Avasare et al. Am J Nephrol 2017;45:99-106  (DOI:10.1159/000453081) Table 2. Transplant and post-transplant characteristics

Predicting Post-Transplant Recurrence of IgA Nephropathy: The Importance of Crescents Avasare et al. Am J Nephrol 2017;45:99-106  (DOI:10.1159/000453081) Table 3. Univariable cox proportional hazards for time from transplant to diagnosis of recurrent IgAN

Predicting Post-Transplant Recurrence of IgA Nephropathy: The Importance of Crescents Avasare et al. Am J Nephrol 2017;45:99-106  (DOI:10.1159/000453081) Fig. 2. Kaplan-Meier curves are shown comparing subjects with <10 vs. ≥10% crescents on native biopsy, for the primary outcome of time to recurrent IgAN post-transplant (a) and the secondary composite outcome of doubling creatinine post-transplant or allograft failure (b).